Comparison of standard triple drugs therapy and sequential regimen for Helicobacter- pylori eradicatio
Phase 2
- Conditions
- Dyspepsia.Dyspepsia
- Registration Number
- IRCT201104226030N5
- Lead Sponsor
- Vice-chancellor for research of Hamadan university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Inclusion criteria : patients in whom Helicobacter pylori infection was detected by endoscopic method, serology, and urease breathe test with C14.
Exclusion criteria:
past history of Helicobacter pylori infection treatment , upper gastero- intestinal surgery,
Gasteric cancer,
renal or liver failure,
breast feeding & pregnant woman.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication of Helicobacter pylori. Timepoint: 4-6 weeks after treatment. Method of measurement: Rate of eradication by Urease breathe test with C14.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of sequential vs. triple therapy for Helicobacter pylori eradication in dyspepsia patients?
How does the sequential regimen in IRCT201104226030N5 compare to standard triple therapy in terms of clinical outcomes and resistance patterns for Helicobacter pylori treatment?
What biomarkers are associated with treatment response to Helicobacter pylori eradication therapies in dyspepsia patients?
What are the potential adverse events and management strategies for sequential and triple drug regimens in Helicobacter pylori eradication trials?
What alternative drug combinations or novel compounds are being explored for Helicobacter pylori eradication alongside trials like IRCT201104226030N5?